Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)

Study identification

• EU PAS number:
  EUPAS1000000229
• Study ID:
  1000000229
• Official title and acronym:
  Administration of elranatamab in the real-world: Treatement patterns, healthcare resource utilization, costs, effectiveness, and safety (ALTITUDE)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned:27/02/2024

Actual:27/02/2024

Study start date

Planned:15/08/2024

Actual:15/08/2024

Date of final study report

Planned:28/02/2026

Actual:04/09/2026

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable